VIDEO: Terns Pharma ‘builds upon pipeline’ of NASH, obesity research

In a Healio video exclusive, Diana Chung, chief development officer at Terns Pharmaceuticals, highlights data on TERN-501, a thyroid hormone receptor beta-agonist for patients with nonalcoholic steatohepatitis.At the 2022 International Liver Congress, Terns conducted five oral and poster presentations on data from three programs, including TERN-501, which recently was evaluated in the company’s first-in-human study. Results showed TERN-501 was safe and well-tolerated in patients across all doses, Chung reported.“We were very excited to be able to present this data at EASL, and itRead More

Generated by Feedzy